Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $36.4615.

JANX has been the topic of several recent research reports. Truist Financial reaffirmed a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Stifel Nicolaus set a $35.00 price objective on Janux Therapeutics in a research note on Friday, August 7th. Piper Sandler dropped their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday, May 11th.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider directly owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of JANX. Nano Cap New Millennium Growth Fund L P acquired a new stake in Janux Therapeutics in the fourth quarter valued at approximately $34,000. Versant Capital Management Inc grew its holdings in Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after purchasing an additional 784 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Janux Therapeutics during the fourth quarter worth $51,000. Osaic Holdings Inc. increased its position in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares in the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Janux Therapeutics by 2,290.0% during the 2nd quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock valued at $84,000 after purchasing an additional 5,267 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX opened at $18.89 on Thursday. The company has a 50 day moving average price of $15.95 and a 200-day moving average price of $14.75. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The stock has a market capitalization of $1.15 billion, a PE ratio of -11.52 and a beta of 2.50.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million. Equities research analysts forecast that Janux Therapeutics will post -1.76 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.